{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:15:26Z","timestamp":1792023326780,"version":"4.4.0"},"reference-count":57,"publisher":"Impact Journals, LLC","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,22]]},"DOI":"10.18632\/oncotarget.12266","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T22:15:39Z","timestamp":1475705739000},"page":"76534-76550","source":"Crossref","is-referenced-by-count":287,"title":["Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition"],"prefix":"10.18632","volume":"7","author":[{"given":"Junko","family":"Murai","sequence":"first","affiliation":[{"name":"Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc., Novato, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying K.","family":"Yu","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc., Novato, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Ru","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc., Novato, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Wen","family":"Tang","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"},{"name":"Current affiliation: Division of Blood and Marrow Transplantation, Department of Medicine, Stranford University School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiao","family":"Shen","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc., Novato, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Pommier","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,9,27]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Poirier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Ashworth","year":"2013","journal-title":"Clin Cancer Res"},{"key":"3","doi-asserted-by":"crossref","first-page":"10493","DOI":"10.1016\/S0021-9258(19)70490-6","article-title":"ADP-ribosylation in mammalian cell ghosts. Dependence of poly(ADP-ribose) synthesis on strand breakage in DNA","volume":"255","author":"Gill","year":"1980","journal-title":"J Biol Chem"},{"key":"4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/283593a0","article-title":"(ADP-ribose)n participates in DNA excision repair","volume":"283","author":"Shall","year":"1980","journal-title":"Nature"},{"key":"5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Helleday","year":"2005","journal-title":"Nature"},{"key":"6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Smith","year":"2005","journal-title":"Nature"},{"key":"7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Pommier","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"8","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Pommier","year":"2012","journal-title":"Cancer Res"},{"key":"9","volume-title":"PARP inhibitors for Cancer Therapy","author":"Sharma","year":"2015"},{"key":"10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1042\/BJ20102162","article-title":"ATR signalling: more than meeting at the fork","volume":"436","author":"Cortez","year":"2011","journal-title":"Biochem J"},{"key":"11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Cimprich","year":"2014","journal-title":"Nat Cell Biol"},{"key":"12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ceb.2009.01.017","article-title":"ATR\/Mec1: coordinating fork stability and repair","volume":"21","author":"Gasser","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"13","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1128\/MCB.02278-06","article-title":"The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and -DNA Fiber Analyses","volume":"27","author":"Pommier","year":"2007","journal-title":"Mol Cell Biol"},{"key":"14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/emboj\/17.1.159","article-title":"Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints","volume":"17","author":"Friend","year":"1998","journal-title":"EMBO J"},{"key":"15","volume-title":"Faithful DNA Replication Requires Regulation of CDK Activity by Checkpoint Kinases","author":"Seligmann","year":"2011"},{"key":"16","doi-asserted-by":"publisher","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Pommier","year":"2014","journal-title":"Cancer Res"},{"key":"17","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular Pathways: Targeting ATR in Cancer Therapy","volume":"21","author":"Zou","year":"2015","journal-title":"Clin Cancer Res"},{"key":"18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"19","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1158\/1535-7163.MCT-10-0106","article-title":"Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines","volume":"9","author":"Doroshow","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"20","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-15-0335","article-title":"Using CellMiner 1","volume":"21","author":"Pommier","year":"2015","journal-title":"6 for Systems Pharmacology and Genomic Analysis of the NCI-60. Clin Cancer Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"e30317","DOI":"10.1371\/journal.pone.0030317","article-title":"Functional categories associated with clusters of genes that are co-expressed across the NCI-60 cancer cell lines","volume":"7","author":"Pommier","year":"2012","journal-title":"PLoS One"},{"key":"22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.dnarep.2015.01.011","article-title":"Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity","volume":"28","author":"Pommier","year":"2015","journal-title":"DNA Repair (Amst)"},{"key":"23","doi-asserted-by":"publisher","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Pommier","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"24","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.18632\/oncotarget.6413","article-title":"Epigenetic inactivation of the putative DNA\/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs","volume":"7","author":"Esteller","year":"2016","journal-title":"Oncotarget"},{"key":"25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Murray","year":"2012","journal-title":"Nature"},{"key":"26","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1158\/1078-0432.CCR-14-2112","article-title":"SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma","volume":"21","author":"Pommier","year":"2015","journal-title":"Clin Cancer Res"},{"key":"27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1186\/s12885-015-1840-6","article-title":"High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment","volume":"15","author":"Wang","year":"2015","journal-title":"BMC Cancer"},{"key":"28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.15252\/embr.201540964","article-title":"SLFN11 inhibits checkpoint maintenance and homologous recombination repair","volume":"17","author":"Huang","year":"2016","journal-title":"EMBO Rep"},{"key":"29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1124\/jpet.113.210146","article-title":"Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition","volume":"349","author":"Pommier","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fonc.2014.00042","article-title":"Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors","volume":"4","author":"Lee","year":"2014","journal-title":"Front Oncol"},{"key":"31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nrneurol.2014.100","article-title":"MGMT testing--the challenges for biomarker-based glioma treatment","volume":"10","author":"Reifenberger","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Bradshaw","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1158\/1078-0432.CCR-13-0225","article-title":"Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?","volume":"20","author":"Jonkers","year":"2014","journal-title":"Clin Cancer Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers","volume":"19","author":"Ashworth","year":"2013","journal-title":"Nat Med"},{"key":"35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Finkel","year":"2010","journal-title":"Cell"},{"key":"36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors","volume":"3","author":"Martin","year":"2013","journal-title":"Cancer Discov"},{"key":"37","doi-asserted-by":"publisher","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Harrell","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"38","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrm2852","article-title":"Maintaining genome stability at the replication fork","volume":"11","author":"Foiani","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Wainberg, Rafii, Ramanathan, Mina, Byers, Chugh, Goldman, Sachdev, Matei, Wheler, Henshaw, Zhang, Gallant, et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. Journal of Clinical Oncology. 14; p. 32. doi:","DOI":"10.1200\/jco.2014.32.15_suppl.7522"},{"key":"40","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1","volume":"2","author":"Liu","year":"2012","journal-title":"Cancer Discov"},{"key":"41","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1158\/1078-0432.CCR-14-2572","article-title":"Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program","volume":"21","author":"Houghton","year":"2015","journal-title":"Clin Cancer Res"},{"key":"42","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/1535-7163.MCT-14-0810","article-title":"MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide","volume":"14","author":"Arozarena","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"43","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1158\/1078-0432.CCR-13-1975","article-title":"Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer","volume":"19","author":"Byers","year":"2013","journal-title":"Clin Cancer Res"},{"key":"44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nchembio.1986","article-title":"Correlating chemical sensitivity and basal gene expression reveals mechanism of action","volume":"12","author":"Li","year":"2016","journal-title":"Nat Chem Biol"},{"key":"45","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","article-title":"Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors","volume":"13","author":"Johnson","year":"2015","journal-title":"Mol Cancer Res"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Lok, Gardner, Schneeberger, Ni, Desmeules, Rekhtman, de Stanchina, Teicher, Riaz, Powell, Poirier, Rudin. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clin Cancer Res. 2016. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1040.","DOI":"10.1158\/1078-0432.CCR-16-1040"},{"key":"47","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Earl","year":"2010","journal-title":"Lancet"},{"key":"48","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Carmichael","year":"2011","journal-title":"Lancet Oncol"},{"key":"49","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","article-title":"Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors","volume":"66","author":"Ashworth","year":"2015","journal-title":"Annu Rev Med"},{"key":"50","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","author":"O'Connor","year":"2015","journal-title":"Mol Cell"},{"key":"51","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Surdez","year":"2012","journal-title":"Nature"},{"key":"52","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1158\/0008-5472.CAN-11-3648","article-title":"PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma","volume":"72","author":"Chinnaiyan","year":"2012","journal-title":"Cancer Res"},{"key":"53","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1210\/me.2010-0040","article-title":"Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions","volume":"24","author":"Martinez","year":"2010","journal-title":"Mol Endocrinol"},{"key":"54","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd3216","article-title":"Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements","volume":"9","author":"Doroshow","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"55","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Zhang","year":"2013","journal-title":"Science"},{"key":"56","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"57","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T16:27:12Z","timestamp":1657384032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,27]]},"references-count":57,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2016,11,22]]}},"alternative-id":["12266","27708213"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12266","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,27]]}}}